Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 30;13(4):639-642.
doi: 10.21037/tau-23-563. Epub 2024 Apr 3.

Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

Daniel A González-Padilla  1 , José Daniel Subiela  2 , Felipe Villacampa-Aubá  1
Affiliations
Editorial

Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

Daniel A González-Padilla et al. Transl Androl Urol. .
No abstract available

Keywords: Bladder cancer; UGN-102; ablation; chemoablation; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-563/coif). F.V.A. reports payments by Roche Pharma to give lectures about bladder cancer. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5; discussion 475-7. 10.1016/j.eururo.2005.12.031 - DOI - PubMed
    1. Siracusano S, Silvestri T, Bassi S, et al. Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can J Urol 2018;25:9480-5. - PubMed
    1. González-Padilla DA, González-Díaz A, Guerrero-Ramos F, et al. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia. Urol Oncol 2021;39:76.e9-76.e14. 10.1016/j.urolonc.2020.07.003 - DOI - PubMed
    1. Lee LJ, Kwon CS, Forsythe A, et al. Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews. Clinicoecon Outcomes Res 2020;12:693-709. 10.2147/CEOR.S274951 - DOI - PMC - PubMed
    1. Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 2022;81:75-94. 10.1016/j.eururo.2021.08.010 - DOI - PubMed